Guys, the melanoma development strategy is huge! Not only are they increasing the size of the trial by 10 patients in an expansion study, but they also made mention of upcoming studies. Clearly, the data is going to be great. Companies rarely ever expand studies that are bad. ONCS is notorious for being cheap and trying to save money. They would not be making these moves if data was not great! Get ready for $1 by year's end.